PVCT wil be more valuable after a reverse split......20:1 gets you to Larry's price target by August
OMG...one of the goals must be 'recycled ASCO presentations'......has worked since 2010, and the tradition continues; with the added bennie of another trip to Europe on the investors dime
Thanks for making my point for me. Many little science companies claim they will do their own US sales, most wind up underperforming (see MACK) or failing (see Savient). The Genentech's of the world entered very different markets than companies like AEZS face. Launching a de-novo sales force and expecting to achieve sales numbers based on $ generated by seasoned, efficient big pharma companies if an obvious unrealistic expectation.
might be enough to get a few more warrant conversions so they can limp along for a few more months before further diluting the company outright
You meant to say the repeat Macrelin PIII trial, right? Because they missed on the first outing, burned all that cash, kinda important to keep in mind?
Yea, that SE Asia partner will really drive sales...their nutrition and cosmetics core business is such a good fit. Who is their US sales partner going to be?
compensation committee include travel to Europe, Brazil, China, Australia for frivolous meetings.
As the ship sinks deeper into the cold dark water, the BOD finally clamps down on: compensation, bonus, vacation benefits and compensation for committee participation. Gotta chuckle at the 2014 amendment, and committee chair rearrangements....all to little to late, but at least the legal and SEC pressure is paying off.
They are looking for a CEO with better taste in fine wines that Craig had......considered a move up by the BOD...stay focused on the end game
Getting painful over at IV...bean counters are adding up research expenses, warrant conversion watchers are starting to worry, MGT is traveling overseas, again.....you just can not make this stuff up
Big pharma does not have to do much to lower SP here...MGT and the BOD are doing the job for them
Big pharma is shutting down their R&D groups because it is much more efficient to have investors in small companies take the $ risk for early development, then BP can cherry pick the winners...... which is why PVCT does not have a BP partner....no convincing data in melanoma, liver bumps, breast cancer (remember that one Petie?) or for PH-10
Unfortunately of them, it resonates the same way the ASCO surprise abstract rumor does.
I wonder where that PH-10 MOA data is at?
Yep, this slow motion train wreck is interesting to watch now..funny how no one is asking where the next $ will come from anymore
After admitting to defrauding investors and PIII delays, there really is nothing to pump for PVCT till next year. Even IV has turned to discussions of Roth conversions and dreams of recovering lost treasures.
Compared to BIG PHARMA, let me think...uummm. I wonder where all their earnings come from...cosmetics and milk products?
Any chance Zoptrex improves aging skin conditions too?